Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nose cavity administering formulation of nalmefene

A technology for nasal administration and nalmefene, which is applied in the direction of drug combinations, pharmaceutical formulas, and medical preparations containing active ingredients, etc. It can solve the problems of slow onset of action and achieve stable performance and controllable quality

Active Publication Date: 2007-03-21
广东同德药业有限公司
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Practice has also proved that although the nalmefene hydrochloride injection and oral preparations used clinically have a certain therapeutic effect, the onset of effect is slow, and the onset of effect is 30 minutes after administration. max 1.5 hours or more
However, intravenous and intramuscular injections must be operated by professional medical personnel.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Embodiment 1: Nalmefene hydrochloride spray

[0035] Ingredient Amount

[0036] Nalmefene Hydrochloride 80mg

[0037] Polyvinylpyrrolidone 0.5g

[0038] Laurazone 0.5ml

[0039] Propylene glycol 1.0g

[0040] Ethylparaben 0.1g

[0041] Distilled water to 100ml

[0042] Preparation method: fully stir the above-mentioned amount of polyvinylpyrrolidone, nalmefene hydrochloride, propylene glycol, and lauryl nitrogen statistical ethylparaben to dissolve them all, and finally add distilled water to 100ml. The obtained solution is distributed in a spray pump or a quantitative drop pump.

Embodiment 2

[0043] Embodiment 2: Nalmefene hydrochloride spray

[0044] Ingredient Amount

[0045] Nalmefene Hydrochloride 80mg

[0046] Hydroxypropyl-β-cyclodextrin 2.5g

[0047] Ethylparaben 0.1g

[0048] Mannitol 0.5g

[0049] Macrogol 400 1.0ml

[0050]Distilled water to 100ml

[0051] Preparation method: shake the above amount of nalmefene hydrochloride, hydroxypropyl-β-cyclodextrin, ethylparaben, mannitol and distilled water to dissolve, add the above polyethylene glycol 400, and finally add distilled water to 100ml.

Embodiment 3

[0052] Embodiment 3: Nalmefene hydrochloride spray

[0053] Ingredient Amount

[0054] Nalmefene Hydrochloride 160mg

[0055] Methyl-beta-cyclodextrin 5g

[0056] Ethylparaben 0.1g

[0057] Polyvinyl alcohol 0.5g

[0058] Mannitol 2-4g

[0059] Distilled water to 100ml

[0060] Preparation method: add distilled water to the above amount of nalmefene hydrochloride, methyl-β-cyclodextrin, ethylparaben, polyvinyl alcohol, shake to dissolve all, and finally add distilled water to 100ml.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a nalmefene preparation to be administered through nasal cavity, which comprises nalmefene, namefene free alkali or other pharmaceutically acceptable medicinal salt of nalmefene and absorption promoting agent, a large number of tests have shown that, the nasal cavity administered medicinal preparation by the invention can make the medicament absorbed through the path of nasal mucosa, and enter into blood circulation for actions. The advantages of the preparation include stabilized performance, controlled quality and non-stimulation to nasal cavity.

Description

field of invention [0001] The invention relates to a preparation for nasal cavity administration, in particular to a preparation for nasal cavity administration of nalmefene hydrochloride. Background technique [0002] Nalmefene hydrochloride (nalmefene hydrochloride) is an opioid antagonist, created by the American Ivax / Ohmeda company, and listed in the United States in 1995. It is another new pure opioid receptor antagonist synthesized after naloxone (NALOXONE) and naltrexone (Naltrexone). It can bind to opioid receptors μ, κ, and δ, and has the strongest binding effect on μ receptors. [0003] Nalmefene hydrochloride is a pure opioid receptor antagonist and a derivative of water-soluble naltrexone. Its 6-methylene chemical structure makes it exhibit stronger physiological activity and easier penetration of biological membranes. Its plasma elimination half-life (t 1 / 2 ) is 8.2-8.9h, and similar compound naltrexone (F=5%-20%, t 1 / 2 =2-5h) and naltrexone (F=0%-5%, t 1 / 2...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/485A61P25/32A61P9/04A61P11/00A61P43/00
Inventor 夏敏张同祥
Owner 广东同德药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com